Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • AUD/USD

    0.6495
    -0.0041 (-0.62%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    81.79
    +0.44 (+0.54%)
     
  • GOLD

    2,214.50
    +1.80 (+0.08%)
     
  • Bitcoin AUD

    108,744.84
    +1,253.70 (+1.17%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Where Will Cassava Sciences Be in 1 Year?

Where Will Cassava Sciences Be in 1 Year?

First, the company produced strong results in clinical studies for its potential therapy for Alzheimer's disease (AD), Simufilam. The other reason is the result of Biogen, a competitor, receiving regulatory approval in the U.S. last year for its novel AD treatment -- the first such therapy approved for AD since 2003.